scispace - formally typeset
F

Fergus Shanahan

Researcher at National University of Ireland

Publications -  727
Citations -  59181

Fergus Shanahan is an academic researcher from National University of Ireland. The author has contributed to research in topics: Inflammatory bowel disease & Gut flora. The author has an hindex of 117, co-authored 705 publications receiving 51963 citations. Previous affiliations of Fergus Shanahan include Imperial College London & Mater Misericordiae Hospital.

Papers
More filters
Journal ArticleDOI

p53 is frequently mutated in Burkitt's lymphoma cell lines.

TL;DR: Testing of the mutated p53 cDNAs for gain of transforming activity or loss of growth suppression activity showed that several of the BL mutants were functionally altered from wild‐type p53.
Journal ArticleDOI

Distinct associations of HLA class II genes with inflammatory bowel disease

TL;DR: DR and DQ molecules firmly separate UC and CD on genetic grounds, suggesting that the contribution of the HLA class II genes to the disease susceptibility is quite different for the two disorders.
Journal ArticleDOI

Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?

TL;DR: IBS-like symptoms are common in patients with IBD who are thought to be in clinical remission, but abnormal calprotectin levels suggest that the mechanism in most cases is likely to be occult inflammation rather than coexistent IBS.
Journal ArticleDOI

Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity

TL;DR: Only vancomycin treatment resulted in an improvement in the metabolic abnormalities associated with obesity thereby establishing that while the gut microbiota is a realistic therapeutic target, the specificity of the antimicrobial agent employed is critical.
Journal ArticleDOI

The Fas counterattack: cancer as a site of immune privilege

TL;DR: Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fas ligand might enable many cancers to deliver a pre-emptive strike or counterattack against the immune system.